|
| In this ongoing, open-label Phase II study, 60 biomarker-unselected, treatment-naive patients with resectable NSCLC were randomized to receive two preoperative doses of nivolumab with or without relatlimab antibody therapy.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists presented prime editing approaches to correct L227R- and N1303K-CFTR, two mutations that caused cystic fibrosis and were not eligible for current market-approved modulator therapies.
[Cell Reports Medicine] |
|
|
|
| The authors demonstrated that loss of the Mirlet7b/Mirlet7c2 cluster in T cells predisposed mice to exaggerated cigarette smoke- or nanosized carbon black-elicited emphysema.
[eLife] |
|
|
|
| Investigators observed a significant increase in iron concentration during acute lung injury, accompanied by elevated levels of lipid peroxidation markers such as malonaldehyde and 4-hydroxynonenal.
[Inflammation] |
| |
|
|
| Researchers integrated studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase-YAP signaling axis that promoted residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies.
[Nature Communications] |
|
|
|
| The authors presented the development and validation of lung tumor-on-chip platforms to quickly and precisely measure ex vivo the effects of immune checkpoint inhibitors on T cell-mediated cancer cell death by exploiting the power of live imaging and advanced image analysis algorithms.
[Cell Reports Medicine] |
|
|
|
| Investigators observed that deletion of Nek10 in lung adenocarcinoma cells resulted in dramatic stabilization of β-catenin, suggestive of a Nek10 role in the control of β-catenin turnover.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Researchers identified the oncogenic protein annexin 2 (ANXA2) as a potential interacting patterner of highly accelerated region 1A (HAR1A). HAR1A overexpression enhanced ANXA2 ubiquitination and accelerated its degradation via the ubiquitin–proteasome pathway.
[Cell Death Discovery] |
|
|
|
| Integrative analyses of multiple-omics data revealed that high mobility group nucleosome binding (HMGN) frequently exhibited dysregulation in lung adenocarcinoma.
[Scientific Reports] |
|
|
|
|
| Scientists summarize how the gut-lung axis influences COPD, including the alterations of intestinal microecology, the pathological mechanisms, and the involved immune responses.
[Heliyon] |
|
|
|
|
| Based on the ALINA trial results, the FDA approved alectinib as adjuvant therapy for people with ALK-positive NSCLC.
[National Cancer Institute] |
|
|
|
|
| May 20, 2024
New York, New York, United States & Online |
|
|
|
|
|
| | University of Utrecht – Utrecht, Netherlands |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Texas Health Science Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
